Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral solution containing methocarbamol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing methocarbamol are listed in tablet, injection and suspension forms. No finished methocarbamol product of any kind is listed in solution form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Methocarbamol is a centrally acting skeletal muscle relaxant that compounding pharmacies prepare in oral forms by prescription.
Methocarbamol is a centrally acting skeletal muscle relaxant approved in the United States in 1957. Its exact mechanism is not established; the label says it may work through general depression of the central nervous system and has no direct action on muscle fibers, the motor end plate or nerve fibers. Manufactured methocarbamol tablets (originally sold as Robaxin) and an oral suspension (Atmeksi, for patients 16 and older) are FDA-approved as an adjunct to rest, physical therapy and other measures for relief of discomfort from acute, painful musculoskeletal conditions. Methocarbamol injection carries the same indication, and its label adds that it may help control the neuromuscular signs of tetanus alongside standard care. A prescriber might order methocarbamol compounded in a strength or vehicle not manufactured, or in an allergen-free vehicle. Compounded preparations are not FDA-approved and require a prescription.
Methocarbamol has no boxed warning. It can cause drowsiness and dizziness, so do not drive until you know how it affects you. It adds to the effects of alcohol and other sedating drugs. It may blunt the effect of pyridostigmine, so tell your prescriber if you have myasthenia gravis. MedlinePlus says older adults should not usually take it, and StatPearls notes it is on the Beers list because of falls and confusion. The label says it should not be used in pregnancy, especially early pregnancy, unless your prescriber judges the benefit worth the risk, because fetal and congenital abnormalities have been reported. LactMed has no data on breastfeeding but says it is not a reason to stop; watch the infant for sleepiness and poor feeding. Urine may turn black, blue or green. Call your prescriber or pharmacist about rash or itching.
Methocarbamol's mechanism has not been established; the label attributes it to general CNS depression without direct effect on striated muscle contractility, the motor end plate or the nerve fiber, and StatPearls also describes a proposed anticholinergic inhibition of polysynaptic reflexes. Per the tablet label, plasma elimination half-life is 1 to 2 hours, protein binding 46% to 50%, and metabolism is by dealkylation and hydroxylation with likely conjugation; essentially all metabolites are excreted in urine. Clearance falls about 40% in patients on hemodialysis and about 70% in alcoholic cirrhosis, where half-life is prolonged. Labeled indications: methocarbamol tablets, Atmeksi oral suspension (patients 16 and older) and injection as an adjunct for acute painful musculoskeletal conditions; the injection label also describes use in tetanus. The injection is contraindicated in known or suspected renal pathology because of its polyethylene glycol vehicle, is hypertonic, and is not recommended in epilepsy. Use caution with other CNS depressants and in myasthenia gravis on anticholinesterase agents. Methocarbamol may cause color interference in urine 5-HIAA and VMA screening tests. Dosing is per prescriber. Methocarbamol is not a controlled substance.
Measure each dose with the oral syringe or dosing cup provided, using the milliliter markings. Do not use household spoons. Take it by mouth as your label directs, with or without food as instructed. Rinse the measuring device after use and keep the bottle capped.
Oral solutions are aqueous. Under USP <795>, a preserved solution usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label shows whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
